TriCalm climbs the chart

SAN DIEGO — Cosmederm Bioscience’s Tri-Calm OTC itch relief solution is quickly climbing the anti-itch treatment product chart with growth of 148.2% to a dollar base of $4.9 million for the 52 weeks ended June 14 across total U.S. multi-outlets, according to IRI. That strong base may get a boost of doctor recommendations following a clinical study published in May by the journal Clinical, Cosmetic and Investigational Dermatology that found TriCalm superior to diphenhydramine 2% and hydrocortisone 1%. Cosmederm aggressively is promoting the study through both consumer and doctor communications.

(Click here for the full Category Review.)